CBIGi039-A-1

IPSC0051, LRRK2 R1441H(CBIGi039-A) correction

The cell line is not validated yet.

General

Cell Line

hPSCreg name CBIGi039-A-1
Cite as:
CBIGi039-A-1
Alternative name(s)
IPSC0051, LRRK2 R1441H(CBIGi039-A) correction
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines No similar lines found.
Last update 4th April 2025
Notes Isogenic control for CBIGi0039-A.
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Clinical Biospecimen Imaging and Genetic (C-BIG) Repository (CBIG)
Distributors
Derivation country Canada

External Databases

BioSamples SAMEA117982033

General Information

* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
Subclone of

Donor Information

General Donor Information

Sex male
Ethnicity Creole Haitian

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Synonyms
  • Parkinson Disease
  • Parkinson's disease
  • Parkinson's Disease
Genetic variants
LRRK2 (target)
NM_198578.3:c.4322G>A

External Databases (Donor)

BioSamples SAMEA117982032

Ethics

Also have a look at the ethics information for the parental line CBIGi039-A .
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

The source cell information can be found in the parental cell line CBIGi039-A.
Passage number reprogrammed P17

Reprogramming method

Vector type Non-integrating
Vector Episomal
Is reprogramming vector detectable?
Unknown

Vector free reprogramming

Other

Derived under xeno-free conditions
Unknown
Derived under GMP?
Unknown
Available as clinical grade?
Unknown

Culture Conditions

Surface coating Matrigel/Geltrex
Passage method Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
O2 Concentration 21 %
CO2 Concentration 5 %
Medium mTeSR™ 1
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
NANOG
Yes
TRA 1-60
Yes
SSEA-4
Yes
POU5F1 (OCT-4)
Yes

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
Normal 46, XY
Passage number: P17
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Genetic Modification

Disease/phenotype related modifications
Synonyms
  • Parkinson Disease
  • Parkinson's disease
  • Parkinson's Disease
Genetic modifications
LRRK2 (target)
Isogenic modification
12q12
After CRISPR/Cas 9 editing, Sanger sequencing confirms that the mutation codon CRC (His) has replaced the mutant codon CGC (Arg) (red arrow), correcting the missense mutation R1441H. Note that five silent mutations were introduced in the corrected allele.
Repaired